Biotech · 5 min read
D&O Insurance for Biotech & Life Sciences
Biotech and life-sciences companies raise large amounts of capital against long, uncertain development timelines — and that combination puts directors and officers squarely in the line of fire. Directors and officers (D&O) insurance protects individual directors and officers, and the company itself, against claims of mismanagement, breach of fiduciary duty, and misrepresentation brought by investors, regulators, and competitors. For funded, board-governed biotechs — especially those on an IPO track — D&O is essential: the milestones that move valuations also create the moments where shareholders allege something was misrepresented or mismanaged. D&O is the coverage that protects leadership's personal assets while they steer a high-stakes, capital-intensive business. This guide explains why biotech has a distinctive D&O profile, when investors require the coverage, how it differs from cyber, and what underwriters review. If you've raised institutional capital and your value rides on development milestones, this is the policy that protects the people making the calls.
Why Biotech Has a Distinctive D&O Profile
D&O addresses the claims that come with capital, governance, and high-stakes milestones — not breaches or product defects. Biotech intensifies several of these:
- Investor and securities exposure. Large raises against binary clinical or regulatory milestones create fertile ground for misrepresentation and fiduciary-duty claims, particularly around disclosures.
- IPO-track scrutiny. Companies heading toward public markets face heightened securities exposure, and D&O (including Side C entity coverage for securities claims) becomes critical.
- Long timelines and funding pressure. Extended development cycles and repeated raises mean more financings, more board changes, and more occasions for disputes.
- Side A/B/C structure. D&O is layered: Side A protects individuals when the company can't indemnify them, Side B reimburses the company for indemnifying them, and Side C covers the entity for securities claims.
D&O sits alongside your cyber coverage — see our national overview of directors & officers insurance for the mechanics and our startup insurance guide for the full program.
When Investors Require Biotech D&O
For biotech, the trigger for D&O is usually a financing round, and the requirement tends to scale aggressively as the company moves toward later rounds and public markets.
- Series A and beyond. Institutional investors typically require D&O before or at closing, frequently as a term-sheet condition, as board seats appear.
- Board formation. As outside and independent directors join, personal exposure rises; D&O makes board service feasible for the experienced directors biotech boards want.
- IPO preparation. Approaching a public offering typically prompts a substantial increase in limits and a public-offering-of-securities structure.
Our hub on startup D&O walks through how these requirements appear in term sheets and how to prepare a clean submission.
What Underwriters Review for Biotech D&O
D&O underwriting focuses on financial health, governance, and disclosure practices rather than security controls. For biotech, underwriters pay particular attention to:
- Financials and runway. Burn, runway, and financing plans against development timelines, since funding gaps and insolvency drive D&O claims.
- Pipeline and milestone disclosures. How clinical and regulatory progress is communicated to investors, since disclosure disputes are a leading claim source.
- Cap table and funding history. Clean financings, clear investor relationships, no pending disputes.
- Governance. Board composition, independent directors, board minutes, and corporate hygiene.
Premiums vary with stage, financial health, and limits, but as of 2026 typical market ranges for early-stage biotech D&O programs sit in the four figures and up annually for an initial limit, rising significantly as a company approaches an IPO. These are market ranges as of 2026, not a quote. D&O is one part of a broader picture covered in our guide to management liability insurance.
Get a Biotech D&O Insurance Quote from OnePark Risk
OnePark Risk places D&O, cyber, and tech E&O coverage for venture-backed biotech and life-sciences companies, and we understand how investor requirements and IPO-track exposure shape the program. Request a D&O insurance quote and we'll return options matched to your funding stage, pipeline, and board structure.
Frequently asked questions
When does a biotech startup need D&O insurance?
Most biotechs buy D&O at their first institutional round, where investors typically require it before or at closing. Because biotech raises large amounts early and recruits experienced independent directors, the requirement often appears at Series A or even seed.
Does D&O cover claims about clinical-trial or pipeline disclosures?
D&O can respond to claims that directors and officers misrepresented or mismanaged disclosures, including statements about pipeline progress, subject to the policy terms. Disclosure-related securities claims are a leading source of biotech D&O claims, which is why limits and structure matter as a company approaches an IPO.
Does D&O cover data breaches or research-data theft?
No. D&O covers claims against leadership for mismanagement, breach of fiduciary duty, and misrepresentation. Data breaches and research-data theft fall under cyber. Funded biotechs typically carry both as a coordinated program.
How much D&O does a biotech need before an IPO?
Limits typically increase substantially ahead of a public offering, reflecting heightened securities exposure, and are set with underwriters and counsel based on offering size and market conditions. Many biotechs carry modest limits early and scale them with each round toward the IPO.
This material is general educational information, not legal, tax, or insurance advice. Coverage availability, policy terms, and regulatory requirements vary by state, carrier, and applicant.